Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise performance with ranolazine, a pFOX inhibitor.
Chaitman
Bernard R
BR
St. Louis University School of Medicine, St. Louis, MO, USA.
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D002908:Chronic Disease; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D015444:Exercise / Q000502:physiology; D005080:Exercise Test; D006439:Hemodynamics / Q000187:drug effects / Q000502:physiology; D006801:Humans; D010879:Piperazines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000069458:Ranolazine; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000083:Acetanilides; D000319:Adrenergic beta-Antagonists; D004791:Enzyme Inhibitors; D010879:Piperazines; D000069458:Ranolazine